Mapping the Progress of Alzheimer’s and Parkinson’s Disease

Передняя обложка
Yoshikuni Mizuno, Abraham Fisher, Israel Hanin
Springer Science & Business Media, 31 мар. 2002 г. - Всего страниц: 566
1h The 5 International Conference on the Progress in Alzheimer's Disease and Parkinson's 51 1 Disease took place from March 31 to April 5 \ 2001 in Kroto, Japan. This international 1 conference was organized as a joint Congress with the 9 International Catecholamine Symposium. A total of 1258 clinicians and researchers participated in this joint congress 1h from 38 countries in the world. This book represents the proceedings of the 5 Conference on Alzheimer's and Parkinson's disease. The International Conference on the Progress in Alzheimer's and Parkinson's disease was first launched by Professor Abraham Fisher of Israel and Professor Israel Hanin of USA. The first conference was held in Eilat, Israel in 1985. The second conference was organized in Kyoto, Japan in 1989; the third one in Chicago, USA, in 1993, and the fourth one in Eilat, Israel in 1997. The International Catecholamine Symposium (ICS) is an international meeting devoted to the development of basic as well as clinical research on catecholamines. The first Catecholamine Symposium was held in Bethesda, USA in 1958. Since then this symposium has occurred every 5 years. Professor Toshiharu Nagatsu was appointed as 1h the president of the 9 International Catecholamine Symposium, which was to be held in 200 I also in Japan. Therefore, we decided to organize a joint congress of the two meetings, because there is much overlap in research between Alzheimer's disease, Parkinson's disease, and catecholamines. We thank Professor Nagatsu very much for agreeing to organizing this joint congress.

Результаты поиска по книге

Содержание

UBIQUITINPROTEASOME PATHWAY IS A KEY TO UNDERSTANDING
291
COLOCALIZATION OF PARKIN WITH αSYNUCLEIN IN THE LEWY
297
A SHORT HISTORY OF DOPAMINE AND LEVODOPA
305
FAMOUS PEOPLE WITH PARKINSON DISEASE
311
CLINICAL EVALUATION AND DIFFERENTIAL DIAGNOSIS
321
GAIT DISTURBANCES IN PARKINSONS DISEASE
329
LEVODOPA DOES NOT ENHANCE NIGRAL DEGENERATION
337
AUTONOMIC DISORDERS AND MALIGNANT SYNDROME
349

PS1 INTERACTS WITH AND FACILITATES BCATENIN TURNOVER 73
72
BSECRETASE A TARGET FOR ALZHEIMERS DISEASE
79
PRESENILIN DEPENDENT ySECRETASE PROCESSING OF ẞAMYLOID
91
PS1 IS TRANSPORTED FROM THE MOTONEURONS TO THEIR AXON
101
PRESENILIN1 FUNCTION IN THE ADULT BRAIN
111
NEUROPEPTIDE EXPRESSION IN ANIMAL DISEASE MODELS
117
AMYLOID PATHOLOGY AND CHOLINERGIC NETWORKS
127
INTERACTIONS OF BETAAMYLOID WITH THE FORMATION
139
HISTORICAL OVERVIEW OF GLYCOSAMINOGLYCANS GAGs
145
POTENTIAL ROLE
157
LOW MOLECULAR WEIGHT GLYCOSAMINOGLYCAN BLOCKADE
165
C3 A PROMISING ULTRA LOW MOLECULAR WEIGHT
171
MILD COGNITIVE IMPAIRMENT
177
FUNCTIONAL ACTIVATION STUDIES IN ALZHEIMER PATIENTS
183
THE NEW GENERATION OF ACETYLCHOLINESTERASE INHIBITORS
193
M1 MUSCARINIC AGONISTS AS A THERAPEUTIC STRATEGY
205
PHENSERINE REGULATES TRANSLATION OF BAMYLOID
211
DEVELOPMENT OF ANTIDEMENTIA DRUGS FOR ALZHEIMERS
223
HUMAN NEURAL STEM CELL TRANSPLANTATION IMPROVES
229
BiPGRP78INDUCED MICROGLIAL ACTIVATION AND INCREASE
235
PARKINSONS DISEASE NEUROTOXINS AND THE DOPAMINE
245
GENETIC RISK FACTORS IN PARKINSONS DISEASE
251
INFLAMMATORY CHANGES AND APOPTOSIS IN PARKINSONS
259
CHRONIC COMPLEX 1 INHIBITION REPRODUCES FEATURES
271
NEUTRAL RSALSOLINOL NMETHYLTRANSFERASE AS
277
FAMILIAL PARKINSONISM WITH APATHY DEPRESSION
285
PROGRESS IN THE TREATMENT OF PARKINSONS DISEASE
361
NEUROPROTECTION IN PARKINSONS DISEASE
373
SUSTAINED DOPAMINE AGONISM WITH CABERGOLINE
379
SLEEPINESS AND SLEEP ATTACKS IN PARKINSONS DISEASE
385
NEUROPROTECTION BY DOPAMINE AGONISTS AND APPLICATION
391
PROBLEMS OF LONGTERM LEVODOPA TREATMENT
397
EVALUATION OF ABNORMAL INVOLUNTARY MOVEMENTS
403
MANAGEMENT OF ANXIETY AND DEPRESSION IN PARKINSONS
417
TANDOSPIRONE CITRATE A NEW SEROTONERGIC ANXIOLYTIC
423
STEREOTACTIC SURGERY OF PARKINSONS DISEASE OVER
429
SURGICAL TREATMENT FOR DYSKINESIAS
435
DEEP BRAIN STIMULATION AND NEUROPROTECTION
441
CYCLIC GMPMEDIATED PRECONDITIONING GENE INDUCTION AS
447
NEUROPROTECTIVE PROPERTIES OF GPI1046 A NON
455
FK506 PROTECTS DOPAMINERGIC DEGENERATION THROUGH
463
DEMENTIA WITH LEWY BODIES
473
CHOLINERGIC AND MONOAMINERGIC CORRELATES OF CLINICAL
491
DEMENTIA WITH LEWY
497
ACCUMULATION OF INSOLUBLE αSYNUCLEIN IN HUMAN LEWY
509
ALTERNATIVE TREATMENTS FOR LEWY BODY DISEASE
513
THE NEUROPATHOLOGY OF FRONTOTEMPORAL LOBAR
523
PROGRESS IN PSP AND CBD
531
BIOCHEMICAL ANALYSIS OF TAU AND αSYNUCLEIN
537
INDEX
549
Авторские права

Другие издания - Просмотреть все

Часто встречающиеся слова и выражения

Библиографические данные